Kosuke Doki - Concepedia

Author

Kosuke Doki

University of Tsukuba ORCID

Also Known As

K DOKI, K. Doki, Kosuke DOKI, Kosuke Doki

Publications

773

Citations

H-Index

Concepts

All Affiliations

University of Tsukuba University of Tsukuba Hospital Simcyp (United Kingdom)University of Manchester GTx (United States)

About

Kosuke Doki is an author at University of Tsukuba specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	122
2	Pharmacology	6	6	122
3	Biochemistry	2	2	44
4	Clinical Chemistry	2	2	40
5	Anesthesia	1	1	11

Kosuke Doki

Publications

570

Citations

H-Index

Page 1

	Year	Citations
Co‐administration of proton pump inhibitors delays elimination of plasma methotrexate in high‐dose methotrexate therapy Kunihiro Suzuki, Kosuke Doki, Masato Homma, British Journal of Clinical Pharmacology	2008	159
Virtual bioequivalence for achlorhydric subjects: The use of PBPK modelling to assess the formulation-dependent effect of achlorhydria Kosuke Doki, Adam S. Darwich, Nikunjkumar Patel, European Journal of Pharmaceutical Sciences	2017	57
Guidelines for Therapeutic Drug Monitoring of Cardiovascular Drugs Clinical Use of Blood Drug Concentration Monitoring (JCS 2015)　― Digest Version ― Kazutaka Aonuma, Tsuyoshi Shiga, Hirotsugu Atarashi, Circulation Journal	2017	46
Effects of<i>CYP2D6</i>genotypes on age‐related change of flecainide metabolism: involvement of CYP1A2‐mediated metabolism Kosuke Doki, Masato Homma, Keisuke Kuga, British Journal of Clinical Pharmacology	2009	36
Effect of CYP2D6 genotype on flecainide pharmacokinetics in Japanese patients with supraventricular tachyarrhythmia Kosuke Doki, Masato Homma, Keisuke Kuga, European Journal of Clinical Pharmacology Cardiovascular DiseaseCyp2d6 GenotypeMedicinePhysiologyCardiovascular Pharmacology	2006	33
Effects of Proton Pump Inhibitor Coadministration on the Plasma Concentration of Erlotinib in Patients With Non–Small Cell Lung Cancer Masahiro Ohgami, Takayuki Kaburagi, Atsuhiko Kurosawa, Therapeutic Drug Monitoring	2018	26
Serum flecainide S/R ratio reflects the CYP2D6 genotype and changes in CYP2D6 activity Kosuke Doki, Yukio Sekiguchi, Keisuke Kuga, Drug Metabolism and Pharmacokinetics Molecular PharmacologyBiochemistryCyp2d6 GenotypeMedicinePhysiology	2015	23
Implications of intercorrelation between hepatic CYP3A4‐CYP2C8 enzymes for the evaluation of drug–drug interactions: a case study with repaglinide Kosuke Doki, Adam S. Darwich, Brahim Achour, British Journal of Clinical Pharmacology	2018	22
Simultaneous determination of serum flecainide and its metabolites by using high performance liquid chromatography Kosuke Doki, Masato Homma, Keisuke Kuga, Journal of Pharmaceutical and Biomedical Analysis BiochemistryGas ChromatographyMedicineBioanalysisMass Spectrometry	2004	21
Assessing Potential Drug–Drug Interactions Between Dabigatran Etexilate and a P‐Glycoprotein Inhibitor in Renal Impairment Populations Using Physiologically Based Pharmacokinetic Modeling Kosuke Doki, Sibylle Neuhoff, Amin Rostami‐Hodjegan, CPT Pharmacometrics & Systems Pharmacology	2019	21

Page 1